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Abstract 
 
The overwhelming majority of cervical cancer deaths are caused by a sexually-transmitted virus: 
the human papillomavirus, or HPV (Walboomers et al., 1999). According to the Centers for 
Disease Control and Prevention, about 4,000 American women die from it each year.  A vaccine 
would seem a welcome tool in the fight against this deadly disease. However, the introduction of 
the first HPV vaccine in the United States in 2006 was met by controversy and public opposition 
(Schwartz, Caplan, Faden, & Sugarman, 2007).  This negative reaction to the vaccine was 
centered on attempts by its manufacturer, Merck & Co., Inc., to make it a required childhood 
vaccine for school-aged girls. The attempt to create an HPV vaccination mandate largely failed. 
The reasons for the failure were complex and arose in the context of political opposition, public 
skepticism about vaccines, unresolved scientific questions, and issues of cost. 
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The Human Papillomavirus Threat 
Across the globe each year, more than 500,000 women develop cervical cancer, and close 
to 300,000 women die from it (Jemal, Bray, Center, Ferlay, Ward, & Forman, 2011). Within the 
United States in 2007, 12,280 women were diagnosed with cervical cancer and 4,021 women 
were killed by it (Centers for Disease Control, n.d., Cancers: Cervical Cancer Statistics). Almost 
all of these deaths - more than 99% - were caused by a sexually-transmitted virus: the human 
papillomavirus, or HPV (Walboomers et al., 1999).  This common virus causes other health 
problems, some of them fatal, among both men and women. HPV is now thought to be the cause 
of about 85% of anal cancers, 70% of vaginal cancers, 40% of vulvar cancers, 40% of penile 
cancers, 35% of throat cancers, and 25% of oral cancers (De Vuyst, Clifford, Nascimento, 
Madeleine, & Franceschi, 2009; Parkin & Bray, 2006; Kreimer, Clifford, Boyle, & Franceschi, 
2005). In addition to causing cancers, HPV causes genital warts, which are not generally life-
threatening (since they are usually caused by different types of the virus than those associated 
with cancers) but can have a devastating impact on people's quality of life (National Cancer 
Institute, 2010). 
Given these frightening statistics, one might assume that a vaccine that could prevent 
many of these infections and cancers would be universally welcomed. However, the 2006 
introduction of the first HPV vaccine in the United States, Gardasil (developed by Merck & Co., 
Inc.), was immediately met by controversy and public opposition (Schwartz, Caplan, Faden, & 
Sugarman, 2007). This negative reaction to the vaccine was centered on attempts to make it a 
required childhood vaccine for school-aged girls. The reasons for the reaction are complex and 
involve the intersection of children, sex, politics, economics, religion, public understanding of 
vaccine efficacy and safety, and the role of government interventions for the public good. 
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This paper examines the context within which the Gardasil HPV vaccine was developed, 
the way in which it was introduced to the public, the attempt by the Merck to have it become a 
state-mandated childhood vaccine, and the opposition that the proposed mandate provoked.  The 
system by which new vaccines become recommended for general use in children, and Gardasil's 
encounter with this system, is also described. The factors that led to the general failure of a new 
mandate for HPV vaccination are discussed, partly through a comparison with the previous 
successful development of mandates for hepatitis B vaccinations. A timeline of key events 
concerning the development and launch of Gardasil is provided on pages 24-25. 
The Development and Approval of an HPV Vaccine 
In 1842, the Italian doctor Domenico Rigoni-Stern noticed that cervical cancer was much 
less common among virgins and nuns than among women who had been married; this was the 
first evidence that the cancer could be connected to a sexually transmitted disease. By the early 
1980s, evidence began to indicate that there was a link between cervical cancer and the human 
papillomavirus (McNeil, 2006). Evidence of the link was developed by Harald zur Hausen, a 
German scientist who shared the 2008 Nobel Prize in Medicine for his work (Altman, 2008). Dr. 
zur Hausen first suggested the link between HPV and cervical cancer in 1976 and, through 
further research, more firmly identified a relationship between cervical cancer  and HPV types 
16 and 18 in 1983 (zur Hausen, 1976; Dürst, Gissmann, Ikenberg, & zur Hausen, 1983). Before 
zur Hausen's work, strong evidence was lacking for a causal link between cancer and viruses. 
The link between a virus and cervical cancer opened the possibility of developing a 
cancer vaccine. The basic science behind such a vaccine for cervical cancer was developed by 
Douglas R. Lowy and John T. Schiller, scientists at the National Cancer Institute’s Laboratory of 
Cellular Oncology. They discovered that an immune response could be provoked by the proteins 
  HPV Vaccination Debate    7 
 
in the outer shell of the human papillomavirus (Barr, 2007). This discovery indicated that a 
relatively safe vaccine could be developed that would not require exposure to any form of active 
virus. 
The basic principles developed by Lowry and Schiller set off a race to develop a 
marketable vaccine.  The first new drug approval application in the United States for an HPV 
vaccine was filed with the FDA’s Center for Biologics Evaluation and Research (CBER) by 
Merck  at the end of 2005. On May 18, 2006, CBER’s Vaccines and Related Biological Products 
Advisory Committee met in a public session to review the vaccine and receive input from 
interested parties. The panel recommended approval of the vaccine (Bridges, 2006). The FDA 
approved the vaccine on June 8, 2006.   
As stated in FDA’s approved product information, the Merck vaccine is a quadrivalent 
vaccine that provides immunity against HPV types 6, 11, 16 and 18. Out of more than 100 types 
of HPV, researchers linked about 70% of cervical cancer cases  to types 16 and 18, and about 
90% of genital wart cases to types 6 and 11. Although the genital wart strains generally do not 
cause cervical cancer, they were added to the vaccine as an additional incentive for males to get 
vaccinated, since males can be carriers of the cancer-causing strains.  However, the initial 
marketing approval sought by Merck for the vaccine did not include males. The original Merck 
application and FDA-approved indication in 2006 allowed Gardasil to be administered to 
females from the ages of 9 to 26 (United States Food and Drug Administration [FDA], n.d., 
Gardasil).  
The target population for the new HPV vaccine was potentially vast. According to data 
from the National Health and Nutrition Examination Survey (NHANES) that was collected in 
2003-2004 (prior to the marketing approval of the first HPV vaccine): 
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Prevalence of HPV DNA in a representative sample of US females aged 14 to 59 years 
was 26.8%, with the highest prevalence (44.8%) among women aged 20 to 24 years. The 
overall prevalence of HPV among females aged 14 to 24 years was 33.8%. This 
prevalence corresponds with 7.5 million females with HPV infection. The prevalence of 
high-risk HPV types 16 and 18 were 1.5% (95% CI, 0.9%-2.6%) and 0.8% (95% CI, 
0.4%-1.5%), respectively.  
(Dunne, Unger, Sternberg , et al., 2007) 
 
 
Figure 1: Prevalence of Low-Risk and High-Risk HPV Types  
Among Females Aged 14 to 59 Years, NHANES 2003-2004 
 
 
Error bars indicate 95% confidence intervals. Both low-risk and high-risk HPV types were 
detected in some females. Low-risk HPV types are defined as HPV type 6, 11, 32, 40, 42, 44, 54, 
55, 61, 62, 64, 71, 72, 74, 81, 83, 84, 87, 89, and 91; and high-risk HPV types as HPV type 16, 18, 
26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 73, 82, 85, and IS39 (Dunne, 
Unger, Sternberg , et al., 2007). 
 
Immunization Recommendations 
Following the FDA approval of the vaccine, the next crucial step in establishing the 
broadly accepted use recommendations for Gardasil was its review by the Advisory Committee 
on Immunization Practices (ACIP).  Organized under the auspices of the U.S. Department of 
Health and Human Services and the Centers for Disease Control and Prevention (CDC), the 
ACIP is an advisory panel of fifteen members.  This panel is the sole federal government entity 
with responsibility for developing written recommendations on vaccination practices in the 
United States (Centers for Disease Control and Prevention [CDC], n.d., Advisory Committee on 
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Immunization Practices [ACIP]).  Although the ACIP cannot set legal mandates for childhood 
vaccines (which are the responsibility of the states), its recommendations are considered largely 
authoritative and tend to be followed in establishing vaccination recommendations and 
requirements for various target groups. ACIP recommendations also determine which 
vaccinations will be covered by the federally-funded Vaccines for Children (VFC) Program. 
Administered through Medicaid, this program provides vaccines for free to children who 
otherwise may not receive them because of cost (CDC, n.d., Vaccines for Children Program 
[VFC]). 
The ACIP met on June 29, 2006 to review Gardasil. By a 13-0 vote (two members 
abstained due to conflicts of interest), the committee recommended "routine vaccination of 
females 11-12 years of age with three doses of quadrivalent HPV vaccine. The vaccine series can 
be initiated in females as young as 9 years of age at the discretion of the provider" (CDC, 2006). 
This recommendation established the Gardasil vaccination as a recognized standard of care for 
young girls. 
Formation and implementation of HPV vaccination policies in the United States then 
moved to the state level. The ACIP recommendation of routine HPV vaccination contributed to 
the question of whether it should be added to the lists of mandated vaccines for school children. 
Under the   powers delegated to the individual states by the U.S. Constitution, states are allowed 
to pass laws "reasonably related to the promotion and maintenance of the health, safety, morals, 
and general welfare of the public;‖ this power has been interpreted by case law to include the 
power to require vaccinations for communicable diseases (Dowling, 2008). Vaccination 
mandates vary by state, both in terms of the required vaccines and the exceptions to use that are 
allowed. Every state has mandated vaccines for school children, but exemptions are allowed. All 
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states have exemptions for medical reasons. Forty-eight states (all except Mississippi and West 
Virginia) allow exemptions from vaccinations based on religious belief. Twenty states allow 
exemptions based on non-religious philosophical beliefs (National Conference of State 
Legislatures [NCSL], 2010). 
Vaccination Marketing and Mandates 
Even before receiving FDA approval for Gardasil, Merck began marketing efforts for the 
new vaccine. Its first step was supporting the "Make the Connection" campaign, which was 
intended to publicize the connection between HPV and cervical cancer. The campaign 
distributed bracelet kits and information through a Web site and toll-free number; by January of 
2006, several months before marketing approval for Gardasil, Merck had distributed more than 
100,000 bracelets. (Merck and Co., Inc., 2006) This effort was followed by the "Tell Someone" 
campaign, which encouraged women to talk with others about HPV and cervical cancer. Both of 
these disease awareness campaigns were motivated by Merck's findings that most women were 
unaware of the HPV-cervical cancer link (Herskovits, 2007). In the two months prior to the FDA 
approval, Merck ran more than a thousand TV commercials in its awareness campaign (Zimm & 
Blum, 2006). Then, following the marketing approval in June 2006, Merck launched its direct-
to-consumer marketing campaign that included the first advertisements mentioning Gardasil by 
name. Known as the "One Less" campaign, its commercials features girls making statements 
such as, "―Each year in the U.S., thousands of women learn they have cervical cancer. I could be 
one less‖ (Dederer, 2007). 
Combined with the direct-to-consumer advertising, Merck began an intense lobbying 
effort to have Gardasil added to the list of vaccines mandated for children attending public 
schools (Gardner, 2007). For the vaccine to be maximally effective, it must be administered 
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before recipients become sexually active. Janet Gilsdorf, MD, a member of the ACIP's HPV 
Working Group, stated "We decided to focus on 11 and 12 year olds because there's a strong 
movement afoot to establish adolescent visits [to the doctor] at a time of life when people aren't 
going to the physician for routine care" (Herskovits, 2007). Therefore, the ACIP recommended 
that the best time to administer the vaccine is when children are about 11-12 years old, and a 
school mandate for HPV vaccination would target sixth grade girls. 
If HPV vaccination had become mandatory, it would have had two effects that would 
have benefitted  Merck. First , it would have given Merck a virtually guaranteed large market for 
Gardasil. As the first HPV vaccine to go to market, and as the one that offered protection against 
the greatest number of HPV types (GlaxoSmithKline's Cervarix, which did not received 
marketing approval until October 16, 2009, only protects against HPV types 16 and 18), Gardasil 
was in a good position to become the standard HPV vaccine. Second, if HPV vaccination were to 
become a mandated childhood vaccine, Merck could receive liability protection for injuries 
caused by the vaccine under the auspices of the National Childhood Vaccine Injury Act of 1986. 
This law created the National Vaccine Injury Compensation Program (VICP), which included a 
provision moving injury lawsuits against vaccine makers from the regular state and federal court 
systems into "a no-fault alternative to the traditional tort system for resolving vaccine injury 
claims that provides compensation to people found to be injured by certain vaccines" (United 
States Department of Health and Human Services [HHS], n.d., VICP)  In order for a vaccine to 
be placed under this program, it needs to be recommended by the ACIP, subjected to a federal 
excise tax, and approved for the program by the Secretary of Health and Human Services (HHS, 
n.d., Newly Licensed Vaccines & VICP Coverage).  
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Merck’s proposal for a school vaccination mandate was supported by a number of other 
organizations; among the most prominent was Women in Government, which received funding 
from Merck for some of its lobbying efforts (Women in Government, n.d.; Associated Press, 
2007).
 
 Other organizations, such as the American Cancer Society, Centers for Disease Control 
and Prevention, and the American Academy of Pediatrics also supported widespread use of the 
vaccine, but were wary of supporting a vaccination requirement for school attendance.  In 2006-
2007, immediately following the FDA approval and ACIP recommendation, 41 states as well as 
the Distinct of Columbia introduced legislation to mandate, pay for, or provide information to the 
public about HPV vaccination. Attempts to require use of the vaccine, however, produced a 
backlash from a number of interest groups and segments of the public. 
In September of 2006, Michigan became the first state to introduce proposed legislation 
for an HPV vaccination mandate (Eggert, 2006). Between the fall of that year and the beginning 
of 2007 at least 18 states initiated debate on an HPV vaccination mandate, but in the face of 
controversy a number of states began dropping the proposal (Wyatt, 2007). The biggest public 
battle over a proposed HPV vaccination mandate, however, arose in Texas. At the beginning of 
2007, bills to mandate the vaccine for schoolgirls were under debate in both houses of the Texas 
legislature (Ackerman, 2007).  On February 2, 2007, however, before the bills could become 
law, Governor Rick Perry issued an executive order requiring girls starting the sixth grade by 
September 2008 to receive the vaccine (Hoppe, 2007a). Although the order allowed parents to 
opt out for reasons of religion or conscience, it provoked an immediate and intense backlash. 
Social conservatives, who had previously been among Perry's supporters, attacked the governor 
for interfering with parental rights and encouraging sexual permissiveness (Elliott, 2007). Saying 
that the legislature had not been allowed the opportunity to discuss the mandate or consider its 
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implications, a state senator announced his intention to introduce legislation to overturn the 
executive order (Lewis, 2007). Critics quickly pointed out that Perry and a number of state 
legislators had received campaign donations from Merck, and Perry's former chief of staff had 
become a lobbyist for the pharmaceutical company (Elliott, Ackerman, & Radcliffe, 2007). 
Within three months, the Texas legislature passed a bill that overturned Perry's order (Hoppe, 
2007b). The action and reaction in Texas brought public attention and scrutiny to Merck's active 
political role in promoting a vaccine mandate.  In the midst of the controversy, the events and 
revelations in Texas became the final blow to Merck's strategy.  Merck retreated from its 
position and on February 20, 2007, publicly dropped its national campaign to make Gardasil a 
required vaccine (Pollack & Saul, 2007a). 
Some other states, including North Carolina, North Dakota, Utah, and Washington, 
passed laws requiring the distribution of educational materials on HPV and the vaccine (NCSL, 
2011). Ultimately, however, HPV vaccination requirements associated with school attendance 
only went into effect in Virginia and the District of Columbia, and in both cases broad special 
exemptions were allowed. While all other vaccines with school mandates only allowed 
exemptions for medical or religious reasons, the District of Columbia and Virginia both 
specifically allowed parents to opt their children out of the HPV vaccine for any reason (Stewart, 
2008). 
Political Opposition 
Political opposition to the HPV vaccination mandate came from a variety of sources and 
its roots pre-dated the FDA approval of Gardasil. The movement for abstinence-only sex 
education was one source of opposition. Some of these critics of a vaccination requirement 
began airing their concern that the forthcoming HPV vaccine could give a false sense of security 
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and encourage teenage sexual activity (Stein, 2005). Concerns about high rates of HPV had been 
used by social conservatives for a number of years prior to the advent of Gardasil as a reason for 
supporting abstinence-based sex education. Sandy Rios, president of Concerned Women for 
America, and Robert Knight, a member of the advisory board for the National Abstinence 
Clearinghouse, declared in a 2002 editorial:  
Everyone knows that HIV is fatal. But how many know that at least 5,000 women die 
yearly in the United States from other sexually transmitted diseases (STDs)? Most cases 
of cervical cancer are caused by human papillomavirus (HPV), an STD that infects 
more than 5 million people annually. Condoms are useless against HPV and nearly 
useless against genital herpes. Despite this, the government is still spending millions of 
dollars to persuade kids to have 'safe sex' by using condoms. As the epidemic rages, the 
one bright spot is the success of abstinence programs, which reduce teen sexual activity.  
(Rios & Knight,  2002) 
In the spring of 2005, Bridget Maher, a spokesperson for the Family Research Council, 
asserted that "Giving the HPV vaccine to young women could be potentially harmful, because 
they may see it as a license to engage in premarital sex" (MacKenzie, 2005). Reginald Finger, 
who had served as a medical advisor for the pro-abstinence group Focus on the Family, and was 
a member of the ACIP appointed under President George W. Bush, stated in late 2005 that "If 
people begin to market the vaccine or tout the vaccine that this makes adolescent sex safer, then 
that would undermine the abstinence-only message" (Sheffield, 2005). (Finger, however, 
ultimately supported the ACIP's vaccination recommendation [CDC, 2006].)  
Such sentiments were quickly subjected to intense criticism. As one headline read, 
"Religious right would kill to stop safe sex" (Traister, 2005). Within this atmosphere, 
conservative critics soon backtracked, and by the time the vaccine was approved, few organized 
groups claimed that the vaccine would promote promiscuity (Gibbs, 2006).   
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Conservative opposition to an HPV vaccination mandate narrowed to claims about 
parental choice and concerns about the safety of the vaccine. By 2007, the Family Research 
Council had issued a clarification of its spokesperson's media remarks, and asserted: 
The only public policy measure which we would oppose in promoting the vaccine is an 
effort to make it mandatory for school attendance. Our reason for that is that it would 
infringe upon parental rights to decide their own children's medical care, without 
sufficient public health justification (because HPV is not transmitted through casual 
contact). To repeat, our opposition to mandatory vaccination is rooted in a concern 
about parents' rights, not about sexual behavior.  
(Family Research Council, 2007) 
Despite the backpedalling by prominent organizations, individual parents often objected 
to the vaccine based on concerns that the vaccine could encourage sexual activity or raise a topic 
for which their children were not ready (Wiggins, 2007).  In a survey of California parents, the 
most frequently specified reasons for parents who were unlikely to have their daughters 
vaccinated were concerns about the impact of the vaccination on the girls' sexual behavior. 
However, despite the relative frequency of these concerns, only about 7.6% of the parents said 
they would avoid having their daughters vaccinated because of them (Constantine & Jerman, 
2007). 
Political criticism of the move to mandate HPV vaccinations was not limited to 
conservatives.  Liberal commentators and organizations also questioned the vaccine. Merck’s 
aggressiveness in promoting a requirement for the vaccine led to a suspicion that its health 
claims were motivated by a desire for profits.  It was noted, for example, that Merck faced 
millions in legal fees and payouts over Vioxx, its painkiller that was linked to adverse 
cardiovascular events (Pollack, & Saul, 2007b).  PR Watch, an online publication affiliated with 
the Center for Media and Democracy, published a lengthy investigation on "The Politics and PR 
of Cervical Cancer," which concluded: 
  HPV Vaccination Debate    16 
 
Ironically, there is serious concern that vaccination may in fact create a false sense of 
security that will make reliable and effective Pap screening seem less important and 
cases of HPV infection that develop into cervical cancer more common… While Merck 
and its partners have been working to reach individuals to convince them of their need 
for this vaccine, they have also been pursuing an even more fruitful goal. Merck's hope is 
that most if not all states will mandate a vaccine against HPV as a pre-requisite for 
school attendance. A mandatory vaccination for more than half of the population is the 
financial equivalent of the Holy Grail for a pharmaceutical company.  
(Siers-Poisson, 2007) 
The nature of the disease and rationale for the vaccine were also generally different from 
other required vaccines; most other childhood vaccinations are for highly contagious and air-
borne diseases that can be easily spread within a school context (e.g., measles), but HPV can 
only be spread by intimate contact. This fact led civil libertarians to question whether the 
government had sufficient grounds for requiring HPV vaccinations for school attendance 
(Stewart, 2008). For these critics, expanded government vaccination mandates were part of a 
slippery slope that threatened to become a form of government overreach. 
Others questioned why the vaccine would only be required for girls, ignoring the role of 
males in the spread of HPV.  As one pair of commentators noted, "Issues of fairness arise if 
young girls are compelled to submit to a new vaccine as a condition of receiving publicly funded 
education, when boys are not" (Gostin & DeAngelis, 2007).  
Vaccine Skepticism 
Skepticism about vaccination safety also played a role: Gardasil was introduced at the 
same time that there had been a growing level of popular skepticism about vaccination in 
general.  For example, although scientific studies have refuted the claim, many people have 
come to believe that there is a linkage between some vaccines and autism (McNeil, 2009). In 
1998, Andrew Wakefield published his now-notorious article alleging a link between some 
vaccines and the onset of autism in young children (Wakefield, Murch, Anthony, et al., 1998). 
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By 2000, this allegation had led to Congressional hearings on the issue in the United States, and 
numerous lawsuits by families of autistic children followed (Hilts, 2000; Vedantam, 2007).  A 
number of follow-up studies questioning Wakefield's results, as well as the retraction of his 
original article by The Lancet and later accusations of fraud against him, have so far done little to 
reduce the skepticism about vaccinations that was set in motion (Haris, 2007; Deer, 2011). 
There were no allegations that Gardasil was linked to autism. Among other factors, it did 
not include thimerosal, the mercury-based preservative that was alleged by many to be the root 
cause of the autism link, and the targeted patient population was past the normal age of autism 
onset. However, after the autism controversy became public, it contributed to the climate of 
popular skepticism about vaccinations.  Included with this skepticism was a movement among 
people who felt that vaccinations were in some sense unnatural and that children were better off 
building natural immunity through exposure to some diseases. For instance, there were claims 
that some parents deliberately exposed their children to chicken pox rather than (or in addition 
to) receiving the chicken pox vaccine (Henry, 2005).  
One of the most prominent organizations that promoted skepticism about vaccines, the 
National Vaccine Information Center (NVIC), emphasized concerns about the safety and cost of 
Gardasil.  In a press release, the organization's president was quoted: 
GARDASIL safety appears to have been studied in fewer than 2,000 girls aged 9 to 15 
years and it is unclear how long they were followed up. [The federal Vaccine Adverse 
Event Reporting System] is now receiving reports of loss of consciousness, seizures, 
arthritis and other neurological problems in young girls who have received the shot," 
said NVIC President Barbara Loe Fisher." At the same time, parents who take their 
daughters to private pediatricians are going to be shocked to find that they will be paying 
two to three times the widely publicized $360 cost for the three-dose series. The cost is 
going to break the pocketbooks of parents and break the banks of both insurance 
companies and taxpayers, when the reality is that almost all cases of HPV-associated 
cervical cancer can be prevented with annual pap screening of girls who are sexually 
active.  
(National Vaccine Information Center, 2007) 
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It should be noted that the NVIC failed to assess the costs of annual Pap tests versus the cost of 
the vaccine, and they also did not analyze the comparative availability and reliability of Pap 
tests. Further, the NVIC also did not acknowledge that cervical cancer prevention on the basis of 
Pap test findings often requires surgical intervention. 
Unresolved Scientific Questions 
A number of scientific questions about Gardasil were still unresolved at the time of its 
marketing approval. These unresolved issues led some scientists and public health professionals, 
as well as members of the public at large, to question whether it was appropriate to move swiftly 
toward a vaccination mandate.  
The actual impact of HPV vaccination on cervical cancer rates is unknown. Because an 
HPV infection can take several decades to develop into cervical cancer, the primary endpoint of 
Merck's pivotal clinical trials was not cervical cancer, but instead infection with the HPV types 
covered by the vaccine (Koutsky, Ault, Wheeler, et al., 2002). Although it is almost certain that 
elimination of infections with HPV types 16 and 18 will reduce the incidence of cervical cancer, 
the actual rate of decrease is unknown. Studies have indicated that 30-54% of women in a 
screening population who test positive for HPV have been infected with multiple types; this 
circumstance makes it difficult to clearly attribute cervical cancer occurrences specifically to 
HPV types 16 and 18 (Massad, Einstein, Myers, et al., 2009). There is also the possibility that 
vaccination against only two types of HPV could allow other cancer-causing types of the virus to 
fill "the biological niche left behind after the elimination of HPV types 16 and 18" (Sawaya & 
Smith-McCune, 2007). These conditions make it possible that Gardasil might reduce the risk of 
cervical cancer by less than 70% (the percentage of cervical cancers currently believed to be 
caused by HPV types 16 and 18).  Given this remaining risk from other types of HPV, some 
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health professionals felt that the vaccine could discourage some precautions (e.g., using 
condoms, abstinence) that could reduce the spread of other types of the virus, and it could also 
discourage women from receiving frequent Pap tests, leading to an increase in undetected 
cervical cancers that could subsequently occur (Haug, 2008). 
The long-term efficacy of the vaccine had also not been studied in detail at the time of 
marketing approval. Data from Merck's original clinical trials only provided evidence of an 
antibody response for up to five years after vaccination. It was not known whether a booster shot 
might be needed for the HPV vaccination, although recent data suggests that booster shots are 
advisable for a number of other standard childhood vaccines (Luedtke, 2008). 
The efficacy of the vaccine was primarily tested in female subjects between the ages of 
16-26.  Merck conducted serology bridging studies to examine the immune response of younger 
females in comparison with the response of the subjects in the efficacy trials. These studies 
indicated that the immune response of females 9-15 years old was non-inferior to that of females 
who were 16-23 years old (Merck, n.d.). However, direct efficacy data was not available for 
younger vaccine recipients; this lack of data troubled some critics, who felt that the testing of the 
vaccine on children at the lower end of the approved age range was too limited (Gostin &  
DeAngelis, 2007).  
The newness of the vaccine also caused some hesitation about quickly adopting it as a 
required vaccine. Limited data were available about possible side effects that could emerge only 
after large-scale use, causing some critics to argue that it was premature to make it into a 
required vaccine (Judicial Watch, 2008). Long-term side effects of the vaccine and its long-term 
efficacy were not yet studied; and as noted, it was not yet known if booster shots would need to 
be given to maintain effectiveness (Merck, n.d.).  
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Cost and Delivery Issues 
Gardasil has a complex dosing schedule, requiring three separate injections over a six 
month period; this schedule requires reliable follow-up for children receiving the vaccine.  The 
vaccine is also costly: At $120 per dose for the patient, the base cost for each vaccinated child is 
about $360. On top of this cost, many physicians charge additional office visit fees 
(McCullough, 2007).  These circumstances make Gardasil one of the most expensive vaccines. 
Initially, at least, insurance coverage for the vaccine was unclear and many physicians felt that it 
was inadequate, given the especially high cost of Gardasil.  
Vaccines are generally distributed in a different manner from other drugs, which are 
distributed through pharmacies.  Other than flu vaccines, which are commonly distributed 
through multiple outlets (workplaces, drugstores, etc.), most vaccines are stored and distributed 
directly by doctors. Some practices must invest as much as $50,000 in vaccine inventories, on 
top of refrigeration and supply management. They are also responsible for spoiled inventory and 
must insure the vaccines themselves (Johnson, 2007).  The HPV vaccine would also add to the 
vaccination costs for families. The 12 generally recommended childhood vaccinations can add 
up to a total cost of $1250, and the addition of Gardasil could bring that price to around $1600 
(Stobbe, 2006). 
Discussion and Conclusions 
A confluence of factors led to the reaction against the proposed HPV vaccination 
mandate. These factors become more apparent in a comparison with the introduction of the 
hepatitis B vaccine, which shares a number of attributes with the HPV vaccine. The virus that the 
hepatitis B vaccine protects against is also not spread through casual contact; it is most 
commonly contracted through sexual contact. The vaccine must be given to young children prior 
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to the initiation of sexual activity to be most effective, and the vaccine acts at least in part as a 
protection against cancer. Like Gardasil, the hepatitis B vaccine requires a course of three 
injections over six months.   
Also like Gardasil, the primary hepatitis B vaccines are marketed by Merck. However, 
the hepatitis B vaccine mandates did not generate the amount of controversy and backlash that 
was encountered by Gardasil. The way in which hepatitis B vaccination became universal was 
different from the path pursued by Merck with Gardasil. The hepatitis B vaccine was first 
introduced in 1982, and the ACIP made an initial recommendation that only high-risk groups 
should be vaccinated. However, by the end of the 1980s it became apparent that high-risk groups 
were not being reached in substantial numbers, and the rates of hepatitis B infections and 
subsequent complications did not significantly decline (CDC, 2002). In 1991, the ACIP re-
visited its vaccination strategy; the committee noted that 4,000-5,000 people still died yearly 
from hepatitis B-related diseases, including liver cancer (CDC, 1991)). Selective vaccination had 
been ineffective, in part because of the difficulty of reaching high-risk individuals, and since in 
many cases the source of infection for some people could not be located, so they could not be 
designated as vaccination targets. There were still about 1 million to 1.25 million people in the 
United Sates with chronic hepatitis B infections. Given these circumstances, the ACIP revised its 
recommendations and promoted a strategy that included making hepatitis B vaccination part of 
the standard infant vaccination schedule. (CDC, 1991) 
This strategy to gain infant vaccination was largely implemented through the channels of 
public health professionals. The type of popular media campaign that Merck pursued during the 
approach to the introduction of Gardasil did not take place with the introduction of the hepatitis 
B vaccine. By 1993, a survey of family physicians and pediatricians indicated that most agreed 
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with the latest ACIP recommendations and had adopted them in their practice (Freed, Freeman, 
Clark, Konrad, & Pathman, 1996). In 1994, hepatitis B vaccinations for children were funded 
under the VFC program (Rothman & Rothman, 2009). By the late 1990s, most states and the 
District of Columbia had adopted some form of childhood hepatitis B vaccination mandate, and 
currently all states have one (Immunization Action Coalition, n.d.).   
Despite the similarities between the vaccines, there were a number of circumstances that 
made the HPV vaccination mandate much more difficult to implement than the one for hepatitis 
B. The hepatitis B vaccine was administered to infants rather than adolescents, so the question of 
whether giving a vaccine to prevent a sexually transmitted disease would encourage reckless 
behavior was not an issue. The hepatitis B vaccine was given to both girls and boys, so gender 
issues were not involved. The cost issue was not as large: at about $72 for a full course of three 
shots rather than the $360 base price for Gardasil, the hepatitis B vaccine was substantially 
cheaper (CDC, n.d., CDC Vaccine Price List). Merck also did not run a direct-to-consumer 
advertising campaign for the hepatitis B vaccine, and whatever lobbying efforts it made on the 
vaccine's behalf were less apparent. Also, at the time when the hepatitis B vaccination mandates 
were implemented, Merck had maintained a much more positive public image, ranking among 
the "most admired" companies (Herskovits, 2007). However, in the aftermath of the Vioxx 
scandal, Merck's reputation had been severely damaged (Kolata, 2004). This circumstance 
allowed suspicion to arise about Merck's motives when it began aggressively marketing its 
expensive new vaccine. 
The larger social and political context had also changed from 1982 to 2006.  Public 
suspicion about the safety of vaccines had risen, especially following the scientifically 
discredited claim that there was a link between some vaccines and autism. The Vioxx 
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controversy and other cases of other drugs that had been withdrawn from the market (such as the 
anti-obesity combination drug Fen-Phen) raised awareness of the possibility that new drugs 
could have long-term side effects that might not show up for a number of years.  The movement 
for "abstinence only" sex education had raised suspicions about any government actions, whether 
through sex education classes in public schools or a mandate for a vaccine against a sexually 
transmitted disease, which could conceivably motivate teenagers to engage in sexual activity.  
There were thus multiple factors that led to the failure of the proposed HPV vaccination 
mandate for school girls. The circumstances that derailed the attempt to mandate HPV 
vaccinations suggest that new vaccines face an increasingly complex environment when they are 
introduced to the market. 
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Timeline 
 
1842 Domenico Rigoni-Stern reported that cervical cancer was much less 
common among virgins and nuns than among women who had been 
married. 
 
1976 Harald zur Hausen first suggests a link between HPV and cervical cancer. 
 
1983 Harald zur Hausen publishes the results of a study that shows the presence 
of HPV in the cervical cancer tumors of most of the women under 
observation. 
 
1998 Merck begins human testing of the potential HPV vaccine. 
 
2002 – November Merck announces positive efficacy results in Phase III clinical trial 
involving vaccination against HPV Type 16 virus. 
 
2005 – April Merck announces positive results for Phase III clinical trial of an 
improved version of its vaccine that targets HPV Types 6 and 11 (which 
cause approximately 90% of genital wart cases) and Types 16 and 18 
(which cause approximately 70% of cervical cancer cases). 
 
2006 – May 18 FDA's Vaccines and Related Biological Products advisory panel meets to 
review Merck's HPV vaccine, now called Gardasil. The panel supports the 
vaccine as safe and effective by five separate 13-0 votes. 
 
2006 – June 8 The FDA announces marketing approval for Gardasil for use by females 
aged 9-26. 
 
2006 – June 29 The CDC Advisory Committee on Immunization Practices recommends 
routine HPV vaccination for girls aged 11 and 12, with vaccination also 
permitted for girls 9 or older per their doctor's discretion. 
 
2006 – September Michigan becomes the first state to consider a bill making HPV 
vaccination mandated for sixth grade school girls. 
 
2007 - January 23 A Virginia House of Delegates committee endorses a bill requiring girls 
entering the sixth grade to receive the HPV vaccine. 
 
2007 – February 2 Texas Governor Rick Perry issues an executive order requiring girls 
entering the sixth grade to get the HPV vaccine. 
 
2007- February 20 Merck announces that it will no longer lobby for mandated HPV 
vaccinations for school girls. 
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2007 - May Bill blocking Governor Rick Perry's order for HPV vaccinations becomes 
law without his signature. 
 
2008 – March The CDC announces results of a study indicating that about 1 in 4 
American teenage girls has a sexually transmitted disease, with HPV 
present in 18% of the girls in the study. 
 
2008 - September The FDA approves the marketing of Gardasil for prevention of cancer of 
the vagina and vulva caused by HPV. 
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